NASDAQ · Health care

Jaguar Health, Inc. (JAGX)

Jaguar Health, Inc. brought in $27.8M of revenue over the twelve months to June 30, 2026, up 135.5% from a year earlier. It posted a net loss of $52.4M. At June 30, 2026 it held $3.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 19, 2026.

Watch JAGX in 60 seconds

Price

$7.70

+9.07% on the day · September 25, 2026

52-week range $2.35 to $1,281.00

Market cap

$37.8M

Revenue (last 12 months)

$27.8M

+135.5% year on year

Net margin

-188.5%

What Jaguar Health, Inc. does

Jaguar Health, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker JAGX.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$11.5M	-$45.9M	-$53.6M	-$22.97	n/a
2024	$11.7M	-$30.8M	-$38.5M	-$130.69	-$29.4M
2023	$9.8M	-$34.3M	-$41.9K	-$2,678.17	n/a
2022	$12M	-$34.4M	-$48.4K	-$54,131.95	-$33.2M
2021	$4.3M	-$40.7M	-$52.6K	-$131,993.38	-$35M
2020	$9.4M	-$26.6M	-$33.8M	-$335,576.40	-$15.3M

Full financial statements: income, balance sheet and cash flow

Where JAGX ranks in Health care

Revenue$11.5M

#464 of 646 in Health care · Bottom 28%

Revenue growth-1.5%

#383 of 474 in Health care · Bottom 19%

Net margin-465.4%

#458 of 485 in Health care · Bottom 6%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Jaguar Health, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 25, 2026
Material agreement 8-K
September 24, 2026
Passive stake changed SCHEDULE 13G/A
September 24, 2026
Securities offering prospectus 424B5
September 24, 2026
Material agreement 8-K
September 21, 2026
Shareholder rights changed 8-K
September 18, 2026
Preliminary proxy statement PRE 14A
September 15, 2026
Material agreement 8-K
September 15, 2026
Shareholder rights changed 8-K
September 4, 2026
Other event 8-K
September 3, 2026
Securities offering prospectus 424B5

Recent insider filings (Forms 3, 4 and 144): 10, the latest on March 12, 2026. Insider transactions on SEC

Who owns JAGX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Joshua Mailman13G, passive	9.99%	189,617	September 24, 2026

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about JAGX

What does Jaguar Health, Inc. do?

Jaguar Health, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker JAGX.

Is Jaguar Health, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $52.4M on revenue of $27.8M.

How much revenue does Jaguar Health, Inc. make?

Over the twelve months to June 30, 2026 Jaguar Health, Inc. reported revenue of $27.8M. That is 135.5% more than a year earlier.

When did Jaguar Health, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 19, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 25, 2026.

Similar companies

Compare JAGX with

Compare JAGX with any company

Follow JAGX

Get an email when Jaguar Health, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow JAGX: get an email when it files

Where the numbers come from

Financial figures are the values Jaguar Health, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.